• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Estimation of chronic phase duration in Ph-positive chronic myelocytic leukemia treated with busulfan: statistical analysis on Japanese patients.

作者信息

Hashimoto T, Ohtaki M, Ueoka H, Munaka M, Kuramoto A, Kamada N

机构信息

Institute of Statistical Mathematics, Tokyo, Japan.

出版信息

Int J Hematol. 1994 Jul;60(1):59-69.

PMID:7919239
Abstract

Chronic phase duration was analyzed in 148 Japanese patients with Ph-positive chronic myelocytic leukemia (CML) treated only with busulfan, and multivariate proportional hazard models were constructed to infer the prognosis of a given patient, and to evaluate the prognostic importance of the clinical findings. To make an accurate estimation of an individual patient's prognosis, we introduced a piecewise linear model for describing a hazard function in each prognostic variable. Of the 11 prognostic variables initially analyzed, the absolute count of peripheral basophils was revealed as the most important prognostic factor. A high basophil count was clearly a factor in cases with poor prognosis. The statistical model selection based on the criteria of model approximation finally suggested a model with three covariates; absolute count of peripheral basophils, platelet count, and presence or absence of additional chromosome abnormalities superimposed on the translocation of 9;22. By analyses based on the above model, we estimated that the median of the chronic phase duration for the patients with poor and good prognosis was 12 and 75 months, respectively. The piecewise linear model was well suited for an accurate estimation of an individual patient's prognosis. Thus, the model constructed here would become a reliable control to evaluate investigational approaches, such as hydroxyurea, interferons, and/or bone marrow transplantation.

摘要

相似文献

1
Estimation of chronic phase duration in Ph-positive chronic myelocytic leukemia treated with busulfan: statistical analysis on Japanese patients.
Int J Hematol. 1994 Jul;60(1):59-69.
2
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.甲磺酸伊马替尼治疗对采用α-干扰素方案治疗慢性期早期的费城染色体阳性慢性髓性白血病患者预后的影响分析
Cancer. 2003 Oct 1;98(7):1430-7. doi: 10.1002/cncr.11665.
3
[Multivariate analysis of prognostic factors influencing survival in chronic myelogenous leukemia].[影响慢性粒细胞白血病生存的预后因素的多变量分析]
Rinsho Ketsueki. 1989 Aug;30(8):1180-4.
4
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.甲磺酸伊马替尼用于α-干扰素治疗失败后的费城染色体阳性慢性期髓性白血病:随访结果
Clin Cancer Res. 2002 Jul;8(7):2177-87.
5
[Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].[慢性粒细胞白血病的异基因骨髓移植。70例患者的临床结果及危险因素]
Med Clin (Barc). 1995 Nov 11;105(16):605-11.
6
[A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan].
Rinsho Ketsueki. 1989 May;30(5):625-30.
7
Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.费城染色体阴性、bcr/abl阴性慢性粒细胞白血病患者的特征及预后
Cancer. 2002 Oct 15;95(8):1673-84. doi: 10.1002/cncr.10832.
8
Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.甲磺酸伊马替尼治疗对干扰素耐药或不耐受的慢性期慢性髓性白血病:150例患者的疗效及反应和无进展生存的预后因素
Haematologica. 2003 Oct;88(10):1117-22.
9
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.甲磺酸伊马替尼治疗可改善新诊断的慢性期费城染色体阳性慢性髓性白血病患者的生存率:与历史数据比较。
Cancer. 2003 Dec 15;98(12):2636-42. doi: 10.1002/cncr.11831.
10
High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.慢性粒细胞白血病患者接受高剂量化疗放疗后进行自体费城染色体阴性血液祖细胞移植。
Bone Marrow Transplant. 1996 Feb;17(2):201-5.